Latest news

• Myovant preps US filing for relugolix in prostate cancer

  Myovant is in a head-to-head battle with AbbVie and its rival GnRH inhibitor  Orilissa (elagolix) in endometriosis-related pain and uterine fibroids, but has a clear run at the ... cancer”. It’s also an important development as Myovant has delayed

• AbbVie files blockbuster hopeful elagolix for uterine fibroids

  Will face competition from Myovant rival. AbbVie is gunning for the second indication for its new women’s health product Orilissa, hoping to add uterine fibroids to its FDA approval last ... That raises the question of whether women will be prepared to

• Myovant has second phase 3 trial to back its uterine fibroids drug

  and was due to be filed for the uterine fibroids indication right about now, giving it a few months’ head start. ... Analysts suggest that uterine fibroids could be a $1bn-plus market for GnRH antagonists.

• Myovant’s fibroids drug clears phase 3 trial, but shares sink

  Uterine fibroids are non-cancerous tumours that form in the muscle walls of the uterus and affect between 20% and 80% of women by the age of 50. ... Their drug is already approved as Orilissa to treat endometriosis and has two positive phase 3 readouts

• Urovant slips on phase 3 incontinence drug data

  Others cued up for results include phase 3 trials of Myovant’s relugolix in uterine fibroids, endometriosis and prostate cancer, and Dermavant’s tapinarof in psoriasis.